BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.
Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed
by Zacks Equity Research
Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.
Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up
by Zacks Equity Research
Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.
Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce
by Zacks Equity Research
Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.
Why is Viatris (VTRS) Stock Down 25% in the Year So Far?
by Zacks Equity Research
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Intellia (NTLA) Depreciates 27% Over a Month: Here's Why
by Zacks Equity Research
Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.
Valneva (VALN) Completes Phase III Chikungunya Vaccine Study
by Zacks Equity Research
Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.
Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal
by Zacks Equity Research
While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
by Zacks Equity Research
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
by Zacks Equity Research
On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More
by Zacks Equity Research
Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
by Zacks Equity Research
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)
by Zacks Equity Research
BioDelivery (BDSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.